<DOC>
	<DOCNO>NCT00838370</DOCNO>
	<brief_summary>The primary purpose study prospectively determine whether capecitabine 5-FU-induced toxicity preventable dose reduction prior start first administration patient heterozygous homozygous mutant DPYD*2A , determine whether strategy cost-effective . Secondly , individualized treatment algorithm capecitabine 5-FU therapy DPYD*2A mutant patient develop pharmacokinetic profile capecitabine 5-FU assess .</brief_summary>
	<brief_title>Pharmacogenomic Pharmacokinetic Safety Cost-saving Analysis Patients Treated With Fluoropyrimidines</brief_title>
	<detailed_description>Patients exhibit genetically determine disorder ( DPYD*2A ) metabolic degradation frequently use anticancer agent capecitabine 5-FU ( fluoropyrimidines ) high risk development severe life-threatening toxicity standard treatment compound . Treatment recovery fluoropyrimidine-induced severe toxicity often require prolonged period hospitalization . Screening DPYD*2A patient treat fluoropyrimidine drug subsequent dose adjustment mutant individual prior start therapy possibly reduce number severe toxicity event . Furthermore , reduce frequency and/or duration hospitalization , substantial medical cost save , make cost-effective strategy .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histological proof cancer patient consider treatment capecitabine 5FU hetero homozygous mutant DPYD*2A able willing give write informed consent able willing undergo blood sample pharmacokinetic analysis life expectancy 3 month longer acceptable safety laboratory value ( ANC , platelet count , ASAT , ALAT , creatinine , WHO performance status 02 radio chemotherapy within last 3 week prior study entry patient know alcoholism , drug addiction and/or psychotic disorder suitable adequate followup woman pregnant breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Pharmacogenetics</keyword>
	<keyword>cost-benefit analysis</keyword>
	<keyword>toxicity</keyword>
	<keyword>antineoplastic drug</keyword>
	<keyword>Dihydropyrimidine Dehydrogenase</keyword>
</DOC>